| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| P356 | DOI | 10.1016/J.BIOPSYCH.2005.02.023 |
| P698 | PubMed publication ID | 15953491 |
| P50 | author | Stefan Leucht | Q28036857 |
| Werner Kissling | Q28036859 | ||
| P2093 | author name string | John M Kane | |
| Raymonde Busch | |||
| Johannes Hamann | |||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1543-1549 | |
| P577 | publication date | 2005-06-01 | |
| P1433 | published in | Biological Psychiatry | Q4914961 |
| P1476 | title | Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended | |
| P478 | volume | 57 |
| Q37998840 | A quantitative review of the profile and time course of symptom change in schizophrenia treated with clozapine. |
| Q35688404 | A retrospective observational study of the effectiveness of paliperidone palmitate on acute inpatient hospitalization rates |
| Q29395121 | All Roads to Schizophrenia Lead to Dopamine Supersensitivity and Elevated Dopamine D2High Receptors |
| Q87095474 | Amygdalohippocampal neuroplastic changes following neuroleptic treatment with quetiapine in first-episode schizophrenia |
| Q30455338 | Antipsychotic drug effects in schizophrenia: a review of longitudinal FMRI investigations and neural interpretations |
| Q38056641 | Antipsychotic treatment response in schizophrenia |
| Q26745506 | Antipsychotic-induced sensitization and tolerance: Behavioral characteristics, developmental impacts, and neurobiological mechanisms |
| Q94336980 | Aripiprazole versus ziprasidone for schizophrenia |
| Q95937928 | Association study between HTR2A rs6313 polymorphism and early response to risperidone and olanzapine in schizophrenia patients |
| Q46070389 | Avoidance-suppressing effect of antipsychotic drugs is progressively potentiated after repeated administration: an interoceptive drug state mechanism |
| Q35109168 | Clinical predictors of therapeutic response to antipsychotics in schizophrenia |
| Q37076476 | Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia |
| Q48165168 | Clozapine normalizes prefrontal cortex dopamine transmission in monkeys subchronically exposed to phencyclidine |
| Q36909124 | Conceptual and methodological issues in the design of clinical trials of antipsychotics for the treatment of schizophrenia. |
| Q30458533 | Contextual and behavioral control of antipsychotic sensitization induced by haloperidol and olanzapine |
| Q38364288 | Cost-effectiveness of early responders versus early nonresponders to atypical antipsychotic therapy |
| Q84594464 | Critical trial-related criteria in acute schizophrenia studies |
| Q51993120 | Cyproheptadine resembles clozapine in vivo following both acute and chronic administration in rats. |
| Q91975680 | Differential benefits of olanzapine on executive function in schizophrenia patients: Preliminary findings |
| Q48441064 | Differential effects of haloperidol and olanzapine on the expression of erythropoietin and its receptor in rat hippocampus and striatum |
| Q43678441 | Early improvement as a predictor of treatment response and remission in patients with schizophrenia: a pooled, post-hoc analysis from the asenapine development program |
| Q43989313 | Early improvement on antipsychotic treatment as a predictor of subsequent response in schizophrenia: analyses from ziprasidone clinical studies |
| Q37409087 | Early nonresponse determined by the clinical global impressions scale predicts poorer outcomes in youth with schizophrenia spectrum disorders naturalistically treated with second-generation antipsychotics |
| Q33269867 | Early onset of treatment effects with oral risperidone |
| Q40881518 | Early response or nonresponse at week 2 and week 3 predict ultimate response or nonresponse in adolescents with schizophrenia treated with olanzapine: results from a 6-week randomized, placebo-controlled trial. |
| Q34029290 | Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia |
| Q34660736 | Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia |
| Q48960835 | Early striatal hypertrophy in first-episode psychosis within 3 weeks of initiating antipsychotic drug treatment. |
| Q28580029 | Erythropoietin prevents haloperidol treatment-induced neuronal apoptosis through regulation of BDNF |
| Q48933903 | Evidence-based pharmacotherapy of schizophrenia |
| Q37422493 | Expected clinical benefits of paliperidone extended-release formulation when compared with risperidone immediate-release. |
| Q37076279 | Feasibility of reducing the duration of placebo-controlled trials in schizophrenia research |
| Q52675080 | Five novel loci associated with antipsychotic treatment response in patients with schizophrenia: a genome-wide association study. |
| Q36951758 | Genomics and the future of pharmacotherapy in psychiatry |
| Q34415975 | Gray matter in first-episode schizophrenia before and after antipsychotic drug treatment. Anatomical likelihood estimation meta-analyses with sample size weighting. |
| Q48541253 | Haloperidol Selectively Remodels Striatal Indirect Pathway Circuits |
| Q35175354 | Hippocampal dysregulation of dopamine system function and the pathophysiology of schizophrenia |
| Q89458401 | How Many Patients With Schizophrenia Do Not Respond to Antipsychotic Drugs in the Short Term? An Analysis Based on Individual Patient Data From Randomized Controlled Trials |
| Q30457477 | How antipsychotics work-from receptors to reality |
| Q33816366 | Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophrenia |
| Q24186772 | Increasing antipsychotic dose versus switching antipsychotic for non response in schizophrenia |
| Q79845789 | Linking the PANSS, BPRS, and CGI: clinical implications |
| Q37818035 | Maintenance strategies in schizophrenia. |
| Q34037969 | Metabolic, endocrinologic and cardiac effects of amisulpride: a 24-week follow-up study |
| Q41449760 | Methodological issues in assessing changes in costs pre- and post-medication switch: a schizophrenia study example |
| Q30459624 | Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia |
| Q36074345 | Neural basis of the potentiated inhibition of repeated haloperidol and clozapine treatment on the phencyclidine-induced hyperlocomotion |
| Q89747397 | Neurometabolic correlates of 6 and 16 weeks of treatment with risperidone in medication-naive first-episode psychosis patients |
| Q34855041 | Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial |
| Q34726953 | Past and Present Progress in the Pharmacologic Treatment of Schizophrenia |
| Q24604457 | Pharmacologic treatment of schizophrenia |
| Q33709704 | Predictors of switching antipsychotic medications in the treatment of schizophrenia |
| Q49047575 | Psychopharmacology: A house divided |
| Q34486230 | Quetiapine versus aripiprazole in children and adolescents with psychosis--protocol for the randomised, blinded clinical Tolerability and Efficacy of Antipsychotics (TEA) trial |
| Q26863435 | Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives |
| Q60062678 | Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre 1H-MRS study (OPTiMiSE) |
| Q35566098 | Response trajectories to clozapine in a secondary analysis of pivotal trials support using treatment response to subtype schizophrenia |
| Q48798088 | Safety of amisulpride in combination with antidepressants under common clinical practice conditions |
| Q45332888 | Should early improvement be re-defined to better predict the maintenance of response in first-episode schizophrenia patients? |
| Q48381678 | Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response--a double-blind PET study in schizophrenia |
| Q24187478 | Switching antipsychotic for non response in schizophrenia |
| Q34480502 | The "delayed onset" of antipsychotic action--an idea whose time has come and gone. |
| Q40014174 | The GRM7 gene, early response to risperidone, and schizophrenia: a genome-wide association study and a confirmatory pharmacogenetic analysis |
| Q38979325 | The SWITCH study: rationale and design of the trial. |
| Q60637427 | The acute and long-term effectiveness of amisulpride in patients with schizophrenia: results of a 12-month open-label prospective follow-up study |
| Q59738838 | The different trajectories of antipsychotic response: antipsychotics versus placebo |
| Q22242827 | The dopamine hypothesis of schizophrenia: version III--the final common pathway |
| Q34581127 | The nature of relapse in schizophrenia |
| Q43012056 | The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naïve patients with first-episode schizophrenia treated with risperidone |
| Q48514877 | Time course of the antipsychotic effect and the underlying behavioral mechanisms |
| Q30467216 | Time course of the attenuation effect of repeated antipsychotic treatment on prepulse inhibition disruption induced by repeated phencyclidine treatment |
| Q33890123 | Trajectories and antecedents of treatment response over time in early-episode psychosis |
| Q51249633 | Trajectories of symptom dimensions in short-term response to antipsychotic treatment in patients with a first episode of non-affective psychosis. |
| Q36600801 | Treatment Response in First-episode Schizophrenia |
| Q35828559 | Treatment of early non-response in patients with schizophrenia: assessing the efficacy of antipsychotic dose escalation |
| Q34587166 | Unanswered questions in schizophrenia clinical trials |
| Q41529086 | Update on the management of symptoms in schizophrenia: focus on amisulpride |
| Q43762923 | Volume increases in putamen associated with positive symptom reduction in previously drug-naive schizophrenia after 6 weeks antipsychotic treatment. |
Search more.